Marker Therapeutics to Present at Two Upcoming March Investor Conferences
08 March 2022 - 8:05AM
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that Anthony H. Kim, Chief Financial Officer of Marker
Therapeutics, will present at two upcoming investor conferences in
March.
Conference Details
ROTH Annual ConferenceFireside ChatDate:
Monday, March 14, 2022Time: 11:00 a.m. ET
Oppenheimer Virtual Annual Healthcare
ConferencePresentationDate: Thursday, March 17, 2022 Time:
10:40 a.m. ET
Webcasts of the presentations will be accessible in the
Investors section of the Company’s website
at markertherapeutics.com and will be available for replay
following the events.
About Marker Therapeutics,
Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker’s cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient’s immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cell
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
Investors and Media
Contacts
Marker Therapeutics:
Neda SafarzadehVice President/Head of Investor
Relations, PR & Marketing(713)
400-6451Investor.Relations@markertherapeutics.com
Solebury Trout:
MediaAmy
BonannoAbonanno@soleburytrout.com
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2024 to May 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From May 2023 to May 2024